Early antiretroviral therapy linked with bone loss in patients with HIV

Current HIV treatment guidelines now recommend initiating antiretroviral treatment (ART) at the time of diagnosis. However, a new study has found that such early ART causes greater bone loss compared with deferring ART.

The study followed 399 participants (195 immediate ART and 204 deferred ART) for an average of 2.2 years. Although the study revealed a negative effect on of immediate ART, the overall benefits of ART for preventing HIV transmission and adverse health outcomes prevail. It will be important to understand the long-term consequences of reductions in associated with ART and whether these reductions continue or stabilise with longer therapy.

"What we found was that starting treatment is also associated with accelerated bone loss of about 2-4%, and the rate of decline then appears to slow after the first 2 years of treatment, compared with HIV positive people who deferred treatment," said Prof. Jennifer Hoy, lead author of the Journal of Bone and Mineral Research study. "We have no cure for HIV, so is for life. An increased rate of may become important years later, in the setting of increased risk of fragility fracture."


Explore further

Assessment of bone density and fracture history can predict long-term fracture risk

More information: Jennifer F Hoy et al, Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial, Journal of Bone and Mineral Research (2017). DOI: 10.1002/jbmr.3183
Provided by Wiley
Citation: Early antiretroviral therapy linked with bone loss in patients with HIV (2017, June 26) retrieved 6 August 2020 from https://medicalxpress.com/news/2017-06-early-antiretroviral-therapy-linked-bone.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments